



Oxygen Uptake, Ventilation, and Symptoms During
Low-Frequency Versus High-Frequency NMES in
COPD: A Pilot Study.
Citation for published version (APA):
Sillen, M. J., Wouters, E. F. M., Franssen, F. M., Meijer, K., Stakenborg, K. H., & Spruit, M. A. (2011).
Oxygen Uptake, Ventilation, and Symptoms During Low-Frequency Versus High-Frequency NMES in
COPD: A Pilot Study. Lung, 189(1), 21-26. https://doi.org/10.1007/s00408-010-9265-0





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 02 Nov. 2021
COPD
Oxygen Uptake, Ventilation, and Symptoms During
Low-Frequency Versus High-Frequency NMES in COPD:
A Pilot Study
Maurice J. H. Sillen • Emiel F. M. Wouters •
Frits M. E. Franssen • Kenneth Meijer •
Koen H. P. Stakenborg • Martijn A. Spruit
Received: 15 September 2010 / Accepted: 25 October 2010 / Published online: 16 November 2010
 Springer Science+Business Media, LLC 2010
Abstract Transcutaneous neuromuscular electrical stim-
ulation (NMES) involves the application of an electrical
current through electrodes placed on the skin over the
targeted muscles. During high-frequency NMES
(HF-NMES), oxygen uptake, minute ventilation, and the
degree of symptom perception (dyspnea and fatigue) have
been shown to be acceptable in chronic obstructive pul-
monary disease (COPD). Currently, oxygen uptake and
ventilation load have never been assessed during low-fre-
quency NMES (LF-NMES) of the lower-limb muscles. The
purpose of this study was to compare prospectively oxygen
uptake, ventilation, and symptom perception during a sin-
gle session of LF-NMES versus a single session of
HF-NMES of quadriceps muscles in patients with COPD.
In 17 COPD patients (mean FEV1 = 45% predicted, mean
body mass index = 26.2 kg/m2), peak exercise capacity,
functional exercise capacity, and the Medical Research
Council dyspnea grade were evaluated. In addition, oxygen
uptake, minute ventilation, heart rate, and Borg symptom
scores were assessed during one session of LF-NMES
(15 Hz) and one session of HF-NMES (75 Hz) and com-
pared with peak values. Mean oxygen uptake (LF-NMES:
327 ml/min vs. HF-NMES: 315 ml/min), minute ventila-
tion (LF-NMES: 14 L vs. HF-NMES: 15 L), and heart rate
(LF-NMES: 86 BPM vs. HF-NMES: 83 BPM) were similar
during both NMES frequencies. Patients used a relatively
low proportion of their peak aerobic capacity during both
NMES sessions (LF-NMES: 34% vs. HF-NMES: 33%;
P = 0.397). In addition, symptom Borg scores for dyspnea
and leg fatigue were also comparable. Oxygen uptake,
ventilation, and symptoms of dyspnea and fatigue were
comparable and tolerable during LF-NMES and HF-NMES
in patients with COPD. Therefore, LF-NMES and
HF-NMES may both be suitable rehabilitative modalities
to be used in severely dyspneic patients with lower-limb
muscle dysfunction.
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MRC Medical Research Council dyspnea scale
MVV Maximal voluntary ventilation
(MVV = 40*FEV1)
% MVV Percentage maximal voluntary ventilation
6MWD Distance achieved by the 6-min walking test
NMES Transcutaneous neuromuscular electrical
stimulation
Peak HR Peak heart rate
Peak VE Peak minute ventilation (in liters, L)
Peak VO2 Peak oxygen uptake (in ml/min)
% pred Percentage predicted value
VC max Maximum vital capacity
Introduction
Lower-limb skeletal muscle dysfunction (e.g., quadriceps
weakness and/or loss of quadriceps muscle endurance) is a
common extrapulmonary manifestation of chronic
obstructive pulmonary disease (COPD) [1–3] and contrib-
utes to a poor exercise performance, increased use of health
care, and mortality in COPD patients [4–6]. Daily physical
inactivity partially determines skeletal muscle dysfunction
in COPD [7]. Therefore, these patients have a clear indi-
cation for pulmonary rehabilitation [8, 9].
Exercise-based rehabilitation programs are able to
improve lower-limb muscle strength and endurance, func-
tional exercise performance, and health status in patients
with COPD [10, 11]. Exercise training programs typically
consist of lower-limb endurance/interval training, resis-
tance training, or a combination thereof [12, 13]. Unfor-
tunately, the benefits of these lower-limb endurance
exercises (e.g., treadmill walking and/or stationary erg-
ometry cycling) may be limited in COPD patients due to
exercise-induced dyspnea and ventilatory limitation during
training [14]. Indeed, aerobic exercise training can result in
high values of oxygen uptake and ventilation, which exact
a relatively high claim on the peak aerobic capacity of
patients with COPD [14]. Therefore, there is great interest
in new and effective alternative rehabilitative modalities
that do not evoke dyspnea, such as high-intensity resistance
training and transcutaneous neuromuscular electrical
stimulation (NMES) [14, 15].
NMES involves the application of an electrical current
through electrodes placed on the skin over the targeted
muscles, thereby depolarizing motor endplates and, in turn,
inducing skeletal muscle contractions [16, 17]. In patients
with chronic heart failure, low-frequency NMES
(LF-NMES, \50 Hz) increased muscle endurance [18],
whereas high-frequency NMES (HF-NMES, C50 Hz)
increased muscle strength [19]. To date, it remains
unknown which stimulation frequency leads to better gains
in muscle strength and endurance and which stimulation
protocol is optimal for patients with COPD. Indeed, the
effects of LF-NMES are unknown in COPD. Nevertheless,
due to the striking similarities in systemic factors that
contribute to exercise intolerance in patients with COPD or
chronic heart failure [20], a reduced fiber type I proportion
[21], and loss of muscle endurance in COPD [1, 22], it
seems reasonable to hypothesize that LF-NMES will also
have positive effects on quadriceps muscle endurance and
functional exercise capacity in COPD.
Recently, oxygen uptake, minute ventilation, and the
degree of symptom perception (dyspnea and fatigue) have
been shown to be acceptable during a single session of
HF-NMES in patients with COPD [15]. During LF-NMES,
the authors expect also a relatively low and acceptable
oxygen uptake and ventilation, which is comparable to
those during HF-NMES [15]. Currently, this has never been
studied but seems a necessary step prior to a randomized
controlled trial in which the effects of NMES (LF vs. HF)
on lower-limb muscle dysfunction are assessed in COPD.
The purpose of this study was to compare prospectively
oxygen uptake, ventilation, and symptom perception dur-
ing a single session of LF-NMES and a single session of
HF-NMES of the quadriceps muscles in patients with




Seventeen patients (10 men) with clinically stable COPD
[23] were recruited at the start of a comprehensive pul-
monary rehabilitation program at Ciro? in Horn (the
Netherlands) [9]. Patients were considered ineligible to
participate if they had neuromuscular disorders, metal
implants in the lower limbs, a cardiac pacemaker, and/or an
exacerbation of symptoms in the preceding 4 weeks.
Patients with long-term oxygen therapy were excluded
because of the methodology that is used to measure oxygen
uptake and ventilation (e.g., Oxycon Mobile).
Study Design
This was a prospective, randomized crossover pilot study.
The study protocol was approved by the Medical Ethical
22 Lung (2011) 189:21–26
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Committee of the Maastricht University Medical Centre?
(MEC 09-3-004) and conformed to the principles outlined
in the World Medical Association declaration of Helsinki
which was revised in Seoul. Details of the trial were reg-
istered at www.trialregister.nl (NTR1834) before subject
enrolment. All patients gave written informed consent to
take part in the study.
Pulmonary function, body composition (whole-body
dual-energy X-ray absorptiometry), peak cycling load,
peak aerobic capacity, functional exercise capacity, quad-
riceps muscle strength, Borg symptom scores for dyspnea
and fatigue, and the Medical Research Council dyspnea
grade were determined at baseline as a routine part of entry
into the pulmonary rehabilitation program [9, 24]. Coex-
isting morbidities were assessed using the Charlson
comorbidity index (CCI) [25]. Moreover, all patients
underwent a single session of LF-NMES and a single
session of HF-NMES on two separate days within the same
week, in random order. These sessions occurred during the
first week of the rehabilitation program, 0–4 weeks after
the baseline testing. Randomization was performed by
means of a computer-generated randomization list.
Safety was assessed by monitoring adverse events.
Adverse events were defined as changes in health or side-
effects, such as pain and/or muscle cramps, that occurred in
patients who participated in the study while receiving the
treatment.
Methods
During both NMES sessions, continuous online calcula-
tions of breath-by-breath oxygen uptake (VO2) and minute
ventilation (VE) were obtained using the Oxycon Mobile, a
portable metabolic system (CareFusion, San Diego, CA,
USA) (Fig. 1). After calibration, the face mask (Combitox,
Dräger Safety, Lübeck, Germany) was carefully adjusted to
the patient’s face and checked for air leaks. Data were
collected breath by breath and processed using JLAB ver.
5.20b software (CareFusion).
NMES Protocols
During both NMES sessions, bilateral electrical stimulation
of the quadriceps muscles was applied using a portable
electrical stimulator (Gymnex 4, GymnaUniphy N.V.,
Bilzen, Belgium). A total of eight electrodes were placed
on the quadriceps femoris muscles (four on each leg): two
on the vastus medialis, one on the rectus femoris muscle,
and one on the vastus lateralis muscle (Fig. 1). Both
stimulation protocols were preset in the devices. The
stimulation protocol of LF-NMES consisted of a symmet-
rical biphasic square pulse at 15 Hz, a duty cycle of 8 s on
and 2 s off, a pulse time of 390 ls during a session lasting
29 min. The stimulation protocol of the HF-NMES con-
sisted of a symmetrical biphasic square pulse at 75 Hz, a
duty cycle of 6 s on and 29 s off, a pulse time of 410 ls
during a session lasting 21 min. During both sessions the
intensity was increased to maximum individual toleration.
The muscle contractions were visible and palpable. In
addition, Borg symptom scores for dyspnea and leg fatigue
were obtained before and after both NMES sessions [26].
Statistical Analysis
All statistical analyses were performed using SPSS for
Windows ver. 17.0.1 (SPSS, Inc., Chicago, IL, USA).
Continuous data were tested for normality and presented as
mean and standard deviation or as median and interquartile
range (IQR). In addition, two-tailed paired t tests were used
for within-group comparisons. A priori, the level of sta-
tistical significance was set at P B 0.05.
Results
Characteristics
The baseline characteristics of the patients are given in
Table 1. On average, patients had moderate to severe
COPD and the lungs had poor diffusing capacity for carbon
monoxide (Table 1). Most patients were severely dyspneic,
reporting on the MRC dyspnea scale that they had to stop
for breath after walking 100 yards (91.4 m) or after a few
minutes on the level. Moreover, patients had explicit
quadriceps weakness (mean ± SD = 55 ± 12% predicted
[27]), as well as poor functional and peak exercise per-
formance, with a mean ± SD 6-min walk distance of
380 ± 98 m [28], VO2 max and maximal workload during
CPET of 986 ± 260 ml/min and 60 ± 21 W, respectively.
Fig. 1 Measurement of oxygen uptake and minute ventilation during
a session of bilateral NMES of the quadriceps muscles in a male
patient with COPD
Lung (2011) 189:21–26 23
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On average, patients were ventilatory limited at the end of
the cardiopulmonary exercise test, with high Borg scores
for dyspnea and fatigue (Table 1).
Significant comorbidities were present in 10 of 17 (59%)
patients with COPD. Indeed, the median score on the
Charlson comorbidity index was 2 (IQR = 1-2.5) points.
These comorbidities included coronary heart disease
(n = 5), diabetes (n = 3), nonmetastatic solid malignancy
(n = 2), peripheral artery disease (n = 2), chronic heart
failure (n = 1), transient ischemic attack (n = 1), Bech-
terew’s disease (n = 1), and/or peptic ulcer (n = 1). The
following pulmonary maintenance medications were used
by 17 COPD patients who volunteered to participate: short-
acting b2 agonists (n = 8), short-acting anticholinergics
(n = 1), short-acting combined bronchodilators (n = 7),
long-acting b2 agonists (LABA) (n = 3), long-acting an-
ticholinergics (n = 15), inhaled glucocorticosteroids
(alone or in combination with LABA) (n = 16), systemic
glucocorticosteroids (n = 2), xanthine derivatives (n = 3),
antioxidant agents (n = 5), and/or leukotriene modifiers
(n = 1).
LF-NMES Versus HF-NMES
All patients were able to complete both NMES sessions. No
differences in tolerating both frequencies were reported and
no adverse events occurred during either training session.
The effects of LF-NMES and HF-NMES are compared
in Table 2. Mean resting and peak oxygen uptake, minute
ventilation, and heart rate were not significantly different
between LF-NMES and HF-NMES sessions (Table 2).
Indeed, patients used a relatively low proportion of their
peak aerobic capacity, measured previously during a
CPET, during both NMES sessions (LF-NMES, 34%; HF-
NMES, 33%; P = 0.386). Also, Borg symptom scores for
dyspnea and leg fatigue were comparable for both NMES
types (Table 2).
Discussion
The present pilot study is the first to assess oxygen uptake,
ventilation, and symptom perception during a session of
LF-NMES and a session of HF-NMES. Both NMES fre-
quencies appear to be safe and sustainable in dyspneic
COPD patients with comorbidities. Moreover, oxygen
uptake, ventilation, and Borg symptom scores for dyspnea
and leg fatigue were relatively low and comparable
between LF-NMES and HF-NMES.
HF-NMES is a relatively new exercise modality used in
the rehabilitation of (severely) disabled patients with COPD
[17, 29, 30]. For example, 4–6 weeks of HF-NMES to the
quadriceps muscles resulted in improved muscle strength,
exercise capacity, and disease-specific quality of life in
COPD patients who had an abnormal baseline body com-
position or who were too dyspneic to leave their home for a
hospital-based outpatient pulmonary rehabilitation program
[31, 32]. Indeed, HF-NMES has even resulted in faster
mobilization from bed to chair in bed-bound COPD patients
requiring prolonged mechanical ventilation [33]. Therefore,
it seems reasonable to conclude that HF-NMES is safe,
feasible, and beneficial in patients with COPD [29]. Indeed,
international guidelines recommend HF-NMES in patients
with severe chronic respiratory disease with extreme skel-
etal muscle weakness or who are bed-bound [8].
To date, the effects of LF-NMES in COPD patients have
not been studied. Nevertheless, based on the combination
of severe dyspnea at rest and a clear loss of lower-limb
muscle endurance [1], it may be worthwhile to assess the
effects of LF-NMES on the ambulation muscles of patients
with COPD. The present findings provide additional
rationale to assess the effects of LF-NMES in patients with
Table 1 Participant characteristics
Age (years) 67 ± 9
Body weight (kg) 72.7 ± 14.7
BMI (kg/m2) 26.2 ± 4.5
FFMI (kg/m2) 17.5 ± 2.4
FEV1 (% predicted) 45 ± 16
FEV1/VC max (%) 35 ± 8
DLCO (% predicted) 57 ± 22
MRC dyspnea (grade) 4 ± 1
Peak torque quadriceps muscles (% predicted) 55 ± 12
6MWD (m) 380 ± 98
6MWD (% predicted) 63 ± 17
Peak load CPET (W) 60 ± 21
Peak load CPET (% predicted) 52 ± 26
Peak VO2 CPET (ml/min) 986 ± 260
Peak VO2 CPET (% predicted) 66 ± 30
Peak VCO2 CPET (ml/min) 945 ± 281
Peak VE CPET (L) 38 ± 9
Peak VE CPET (% MVV) 93 ± 23
Peak HR CPET (BPM) 119 ± 15
Peak HR CPET (% predicted) 78 ± 8
Borg dyspnea CPET (points) 8 ± 2
Borg fatigue CPET (points) 6 ± 2
Data are presented as mean ± SD
BMI body mass index, FFMI fat-free mass index, FEV1 forced
expiratory volume in 1 s, VC max maximum vital capacity, DLCO
diffusion capacity of the lung for carbon monoxide, MRC Medical
Research Council dyspnea scale, 6MWD distance achieved by the
6-min walking test, peak load maximum workload, CPET cardio-
pulmonary exercise test, peak VO2 peak oxygen uptake in ml/min,
peak VE peak minute ventilation in liters, peak HR peak heart rate,
bpm beats per minute, % pred percentage predicted value, % MVV
percentage maximal voluntary ventilation
24 Lung (2011) 189:21–26
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COPD who are severely disabled by their dyspnea. In fact,
mean peak oxygen uptake, ventilation, and heart rate were
well below maximum values during a session of LF-NMES
and comparable to the values during a session of
HF-NMES (Table 2).
Oxygen uptake, ventilation, and symptoms during a ses-
sion of HF-NMES in the present study corroborate previous
results of our group [15]. Yet again, these findings show that
COPD patients use a clearly lower proportion of their peak
aerobic capacity during a session of NMES compared to a
session of high-intensity lower-limb resistance training [15],
treadmill walking, or stationary cycling [14]. Indeed, the
biphasic current used during the HF-NMES and the
LF-NMES was well tolerated by the patients (e.g., no drop
out from the protocol and no adverse events) and led to
acceptable levels of dyspnea and fatigue in COPD (Table 2).
This pilot study had some methodological limitations
and selected patient characteristics that may limit the
external validity and broad applicability of the present
findings. Only patients without long-term oxygen therapy
were eligible to participate due to the methodology used
[14]. This study included a small number of COPD patients
with a wide range of disease severity and different levels of
physical function. Some of the participants may not be the
typical patient who receives NMES in daily clinical prac-
tice. Indeed, NMES can be particularly useful for severely
disabled patients with COPD [29].
Moreover, oxygen uptake and ventilation was evaluated
during only a single session of LF-NMES and HF-NMES.
Therefore, it is not possible to draw conclusions regarding
the relative values of oxygen uptake and ventilation over
longer periods of training or to identify subpopulations of
patients who may benefit from either technique.
Session time, duty cycle, and pulse duration differed
between both NMES protocols. This was due to the preset
protocols of the commercially available NMES device.
Nevertheless, the impact of these NMES features on the
primary outcome (i.e., oxygen uptake) is expected to be nil.
Finally, magnetic stimulation can also be used as a
nonvoluntary lower-limb muscle training method in
patients with COPD [34]. However, magnetic stimulation
is rather expensive and its clinical applicability in groups of
COPD patients in clinical routine seems challenging.
In conclusion, oxygen uptake, ventilation, and symptom
perception of dyspnea and leg fatigue were sustainably low
and comparable during a single session of LF-NMES and
HF-NMES in patients with COPD. These pilot findings
provide an additional rationale to design randomized con-
trolled trials to compare the effects of LF-NMES and
HF-NMES on lower-limb dysfunction in (severely) dis-
abled patients with COPD.
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